Replimune Group (REPL)
(Delayed Data from NSDQ)
$6.42 USD
+0.27 (4.39%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $6.41 -0.01 (-0.16%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
REPL 6.42 +0.27(4.39%)
Will REPL be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for REPL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for REPL
How Much Upside is Left in Replimune Group, Inc. (REPL)? Wall Street Analysts Think 50.17%
What Makes Replimune Group, Inc. (REPL) a New Buy Stock
REPL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts See a 70.57% Upside in Replimune Group, Inc. (REPL): Can the Stock Really Move This High?
Incyte (INCY) Beats on Q2 Earnings and Revenue Estimates
Is a Surprise Coming for Replimune (REPL) This Earnings Season?
Other News for REPL
The Melanoma Research Foundation to host the New England Miles for Melanoma 5K
Commit To Buy Replimune Group At $5, Earn 10.2% Annualized Using Options
Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting
Replimune Group presents interim results from ARTACUS trial of RP1 monotherapy
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)